ST316 not checked

Sapience Therapeutics

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
2 active
2 in total

What this is

How it works
How it works isn't classified yet
Tested for
Colon Cancer, Metastatic Colon Cancer, Familial Adenomatous Polyposis (FAP)
Main trialPhase 1
“This is an open-label, two-part, phase 1-2 study designed to determine the safety, tolerability, PK, pharmacodynamics (PD), and proof-of-concept efficacy of ST316 administered IV in subjects with selected advanced solid tumors likely to harbor abnormalities of the WNT/β-catenin signaling pathway. The study consists of two phases: a phase 1 dose escalation/regimen exploration phase and a phase 2 expansion phase.”In the company’s words, NCT05848739 on ClinicalTrials.gov
Given with
Lonsurf (Taiho Oncology)Other companies’ drugs in its trials

Other drugs for Colon Cancer

All 68 drugs for Colon Cancer

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 1Active, not recruiting 31 Dec 2026 A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
Phase 1Not yet recruiting 31 Dec 2028 A Safety Study of ST316 in Participants With Familial Adenomatous Polyposis (FAP).
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow ST316

Following is part of Solo: you see every change to ST316 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in